Loading...
•
Mar 31, 2022
Syndax Q1 2022 Earnings Report
Syndax reported financial results and provided a clinical and business update.
Key Takeaways
Syndax Pharmaceuticals reported its Q1 2022 financial results, with a net loss attributable to common stockholders of $37.2 million, or $0.63 per share. The company is advancing its pivotal programs for revumenib and axatilimab, with topline data expected starting in the first half of 2023.
Topline data from revumenib and axatilimab pivotal programs expected starting in 1H23.
Company remains on track for two FDA filings in 2023.
Axatilimab granted Fast Track designation by U.S. FDA for the treatment of cGVHD after failure of two or more lines of systemic therapy.
BEAT-AML and AUGMENT-102 trials assessing revumenib in combination with venetoclax-azacitidine and chemotherapy underway.
Syndax
Syndax
Forward Guidance
Syndax provided financial guidance for the second quarter and full year of 2022.
Positive Outlook
- Research and development expenses are expected to be $30 to $35 million for the second quarter of 2022.
- Total operating expenses are expected to be $38 to $42 million for the second quarter of 2022.
- Research and development expenses are expected to be $130 to $140 million for the full year of 2022.
- Total operating expenses are expected to be $160 to $170 million for the full year of 2022.